17 citations,
January 2011 in “The Korean Journal of Hepatology” Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.
11 citations,
April 2014 in “Journal of Clinical Virology” Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.
10 citations,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
9 citations,
November 2012 in “Hepatology Research” A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
7 citations,
May 2016 in “European Polymer Journal” The new nanocarriers improve how well water-insoluble drugs dissolve and allow for controlled drug release.
6 citations,
October 2016 in “Journal of Chemotherapy” A man lost all his hair as a rare side effect after hepatitis C treatment.
3 citations,
March 2014 in “Annals of Hepatology” A man lost all his hair after stopping hepatitis C treatment and it didn't grow back.
2 citations,
March 2015 in “Hepatitis Monthly” A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.
April 2024 in “Journal of applied cosmetology” Using hyaluronic acid fillers in the temple area of the face can improve looks but has risks, so choosing the right technique and product is important for safety.
January 2014 in “대한피부과학회지” A hepatitis B patient lost hair in patches after starting and stopping a treatment with pegylated interferon alpha2a.
2 citations,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
26 citations,
June 2005 in “Journal of The American Academy of Dermatology” Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.
68 citations,
March 2002 in “Journal of pharmaceutical sciences” Nonionic liposomes are the best for delivering genes to skin cells.
32 citations,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
29 citations,
December 2017 in “Molecular therapy” Enzyme replacement therapy improved multiple symptoms of homocystinuria in mice.
4 citations,
August 2007 in “PubMed” A woman lost all her body hair after hepatitis C treatment, but it started to grow back a year after stopping the treatment.
November 2022 in “JAAD case reports” A man with skin and hair symptoms improved partially with specific treatment.
January 2011 in “Annals of dermatology/Annals of Dermatology” A woman's psoriasis improved after hepatitis C treatment with interferon, despite interferon's risk of worsening skin conditions.
January 2003 in “American Journal of Clinical Dermatology” Various drugs caused different skin reactions, including allergic and inflammatory responses.
1 citations,
January 2014 in “Hair therapy & transplantation” The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.
41 citations,
August 2007 in “European Journal of Gastroenterology & Hepatology” A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.
23 citations,
December 2004 in “Seminars in oncology” Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
21 citations,
April 2010 in “Molecular Medicine Reports” Zinc supplementation may help improve treatment outcomes for chronic hepatitis C.
2 citations,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
63 citations,
February 2013 in “Human cell” PEGL-DOX causes Hand-Foot Syndrome due to skin reactions from prolonged circulation and ROS generation.
52 citations,
October 2010 in “Antiviral Therapy” New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
47 citations,
September 2015 in “Journal of Drug Delivery Science and Technology” Nanoparticulate systems improve drug delivery by controlling release, protecting drugs, changing absorption and distribution, and concentrating drugs in targeted areas.
27 citations,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
21 citations,
August 2003 in “Seminars in oncology nursing” Nurses are crucial in managing chemotherapy side effects for ovarian cancer patients to improve their quality of life.
2 citations,
October 2018 in “Springer eBooks” Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.